A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
Academic Article
Overview
MeSH Major
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Breast Neoplasms
Immunotoxins
Maytansine
Molecular Targeted Therapy
Quinazolines
Receptor, ErbB-2
abstract
T-DM1 is well tolerated and has single-agent activity in patients with HER2-positive MBC who have previously received both approved HER2-directed therapies and multiple chemotherapy agents. T-DM1 may be an effective new treatment for this patient population.
